After discovering the link between NSCLC and mutations in EGFR, small molecule tyrosine kinase inhibitors were developed and are currently being utilized for targeted therapy in EGFR mutant-positive cases [84]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.